Chimera Research Group

previous arrow
next arrow

January 18th Biotech Update

So it looked really bad last Friday and it was quite the comeback rally.  Unfortunately it seems like the broader market is not looking very good and I cannot imagine a scenario with a broader market/risk off move and the sector somehow moves higher.  I guess one can never say never but it seems exceptionally […]

January 14th Biotech Update

It is not going well for the sector.  There just seem to be no buyers at any levels.  I am not sure what will bring the buyers back.  Obviously the biggest component is M&A but keep in mind the sector reaction after MRK bought XLRN.  I have a hard time thinking through big risks.  Drug […]

January 13th Biotech (and Energy) Update

The sector cannot help itself and stress investors.  We are back at the critical level of support and if it breaks then I think there is significantly more downside.  My view is that support will hold until proven otherwise (just as resistance will hold until proven otherwise).  Given the lack of really positive news or […]

January 12th Biotech Update

I think the big news that was going to drop this week has dropped.  There are still a lot of companies I am going to be following up with so there is still plenty to write about but I do not big new news coming.  Given the lack of M&A and some negative news the […]

Mailing List



Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.

Subscribe to Chimera Research Group and proceed with confidence.

Get Started

Recent Press


Log In

JoinLost Password?